Late-Stage Uveitis Study Data Published

Posted on

Positive results from a Phase 3 clinical trial evaluating the efficacy of triamcinolone acetonide suprachoroidal injectable suspension (Xipere) were published in Ophthalmology.

The randomized, controlled, double-masked PEACHTREE study evaluated triamcinolone acetonide suprachoroidal injectable suspension in 160 patients with macular edema associated with noninfectious uveitis. Patients were randomized to receive triamcinolone acetonide suprachoroidal injectable suspension at baseline and at 12 weeks or control. In the treatment group, 47% achieved at least a 15-letter gain in best corrected visual acuity from baseline at 24 weeks compared to 16% in the control group (P < 0.001). Secondary endpoints were also achieved.

No treatment-related serious adverse events were reported. Corticosteroid-associated AEs of elevated intraocular pressure occurred in 11.5% in the treatment group and 15.6% in the control group. Cataract AE rates were 7.3% and 6.3%, respectively.

To read the full abstract, click here

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021